Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
26
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 158
- Registration Number
- NCT02683265
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 120
- Registration Number
- NCT02677519
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 40
- Registration Number
- NCT02555150
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 10
- Registration Number
- NCT02470234
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸Duke Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States
PRC-063 in an ADULT Workplace Environment
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PRC-063 25 mgDrug: PlaceboDrug: PRC-063 35 mgDrug: PRC-063 45 mgDrug: PRC-063 55 mgDrug: PRC-063 70 mgDrug: PRC-063 85 mgDrug: PRC-063 100 mg
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 60
- Registration Number
- NCT02225639
- Locations
- 🇺🇸
AVIDA, Inc., Newport Beach, California, United States
🇺🇸Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
- Prev
- 1
- 2
- 3
- Next